Hillenbrand (NYSE:HI) reported Q2 CY2025 results exceeding revenue expectations, with sales falling by 23.9% year on year to $598.9 million. Full-year revenue guidance of $2.61 billion at the midpoint was 1.1% above estimates, with non-GAAP profit of $0.51 per share beating consensus by 3%. The company has been focusing on strategic initiatives to reduce debt and advance integration and commercial synergy potential in its Food, Health, and Nutrition business. Despite macroeconomic uncertainty, Hillenbrand is looking to capitalize on higher margin, growth markets. Is now the time to buy Hillenbrand?

Hillenbrand’s revenue growth has been sluggish at a 4.4% compounded annual growth rate over the last five years. This quarter, revenue fell by 23.9% year on year to $598.9 million but beat Wall Street’s estimates. Operating margin decreased to 9.4% in Q2, down from 11% in the same quarter last year. Earnings per share (EPS) declined to $0.51 from $0.85 year on year, but beat estimates by 3%. Analysts expect full-year EPS to shrink by 10.4% over the next 12 months. Overall, Hillenbrand’s Q2 results were above expectations but long-term growth and valuation should be considered before buying.

Read more at Stockstory.org – MarketWatch: Hillenbrand (NYSE:HI) Exceeds Q2 Expectations, Full-Year Outlook Slightly Exceeds Expectations